Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
188Re-PTI-6D2 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| 188Re-PTI-6D2 | DRUG | monoclonal antibody |
Inclusion Criteria: * Histologically confirmed Stage IIIc (unresectable) or Stage IV metastatic melanoma; * measurable disease; * at least 18 years of age; * Karnofsky status at least 50%; * life expectancy \> 3 months; * at least 4 weeks since prior therapy; * adequate organ and marrow function de...
Top 20 of 51 competitors
188Re-PTI-6D2 is an investigational small molecule being developed for the treatment of metastatic melanoma. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in patients.
188Re-PTI-6D2 is being developed by Cassava Sciences, Inc., a biopharmaceutical company. The company is conducting clinical research on this investigational drug for metastatic melanoma.
188Re-PTI-6D2 is in Phase 1 clinical development. A Phase 1 trial has been completed, which was an uncontrolled, non-randomized study designed to evaluate the safety of the drug in patients with metastatic melanoma.
188Re-PTI-6D2 has one completed clinical trial, identified as NCT00399113, titled "Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma." This Phase 1 study enrolled 12 patients in Israel and included adults aged 18 years and older.
188Re-PTI-6D2 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for metastatic melanoma. The drug has completed a Phase 1 safety study, but it has not yet received regulatory approval for any use.